Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

106.60 +1.73 (+1.65%)
Streaming Delayed Price Updated: 10:54 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment. 
Via The Motley Fool
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump ↗
Focused on targeted cancer therapies, this biotech firm reported a notable insider sale amid a year of extraordinary stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
From Equity Insider
Via GlobeNewswire
News headline image
The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens
As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In ↗
Via The Motley Fool
News headline image
3 Stocks You’ll Wish You Bought Before 2026 ↗
Via MarketBeat
News headline image
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results ↗
One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results ↗
One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
GEO Shares Down 44% as Fund Sells $9 Million in Stock Amid ICE Allegations and Softer Outlook ↗
GEO’s latest quarter shows a company pulling in record contracts while wrestling with litigation and cooling earnings guidance—here’s what investors need to know. 
Via The Motley Fool
Topics Immigration Regulatory Compliance
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Exploring Celcuity's Earnings Expectations ↗
 
Via Benzinga
News headline image
Celcuity Analyst No Longer Bullish Despite Breast Cancer Therapy Application ↗
FDA accepts NDA for Celcuity's advanced breast cancer therapy. Analyst downgrades stock due to high valuation. Next catalyst is topline data. 
Via Benzinga
News headline image
CELCUITY INC (NASDAQ:CELC) Stock Surges 70% in a Month Following Q3 Earnings Beat and Positive Clinical Data ↗
Celcuity stock surges after a Q3 earnings beat and positive clinical data for its lead drug candidate, gedatolisib. 
Via Chartmill
Topics Earnings
News headline image
Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. ↗
The company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534%. 
Via Investor's Business Daily
News headline image
These stocks are moving in today's session ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Earnings Scheduled For August 14, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Gapping stocks in Monday's session ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results ↗
The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients. 
Via Investor's Business Daily
Topics Government
News headline image
Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
These stocks are moving in today's pre-market session ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Celcuity Q2 Results Highlight Cash Surge ↗
Via The Motley Fool
News headline image
Celcuity (CELC) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Celcuity Expenses Jump 81 Percent ↗
Via The Motley Fool
News headline image
CELCUITY INC (NASDAQ:CELC) Reports Q2 2025 Earnings Miss Amid Clinical Progress in Gedatolisib Trials ↗
Celcuity (CELC) reported Q2 2025 results with a wider-than-expected EPS loss but revenue in line. Clinical progress in breast cancer trials drives investor optimism despite financial misses. 
Via Chartmill
Topics Earnings
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.